All In Biotech

Drug Trial Radar · NCT06228560

Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Multi-center,Randomized,Double-blind Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

202

Actual

Start

Jan 26, 2024

Primary completion

Apr 17, 2025

Study completion Oct 16, 2025

Sponsor

Lead sponsor
Longbio PharmaIndustry
Sponsor type
Industry
First posted
Jan 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase II, multicenter, randomized, double-blind study to evaluatethe efficacy and safety of LP-003 administered subcutaneously as an add-on therapy for the treatment of adult patients aged 18-75 who have been diagnosed with refractory CSU and who remain symptomatic despitestandard-dose H1 antihistamine treatment.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • LP-003Biological

    Liquid in vial

  • PlaceboBiological

    Liquid in vial

  • OmalizumabBiological

    Liquid in vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of participants achieving complete absence of wheals and itching (UAS7 = 0) at week 12Time frame: Week 12

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Hangzhou First People's Hospital

    Hangzhou, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China

  • Wuhan NO.1 Hospital

    Wuhan, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of China Medical University

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The Second XiangYa Hospital of Central South University

    Changsha, Hunan, China

  • Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College

    Nanjing, Jiangsu, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, China

  • the Second Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.